Regeneron

Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD PMLiVE12:56Sanofi FDA Pharma

Sanofi, Regeneron's Dupixent gets FDA approval for COPD Zacks19:37Sanofi FDA Pharma

Is weakness in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock a sign that the market could be wrong given its… Simply Wall St19:36Pharma Stock Market Stock Markets (World)

Amgen’s formulation of Eylea biosimilar saved it from injunction Bloomberg Law20:52Eylea Biotech Pharma

Preliminary injunction denied against Amgen in aflibercept bpcia litigation JD Supra17:34Eylea Biotech Pharma

Sanofi's Dupixent scores double COPD win in US, China pharmaphorum17:11Sanofi China FDA

Regeneron Pharmaceuticals suffers worst month in two years after legal setback Yahoo! US16:16Pharma Biotech

Should you buy the dip on this top growth stock? The Motley Fool11:32Pharma Biotechnology

Sanofi/Regeneron’s Dupixent recommended by Chmp for younger eosinophilic oesophagitis patients PMLiVE12:42Sanofi Pharma Biotech

Regeneron Pharmaceuticals: Ipr&d charge to negatively impact Q3 EPS by approx. $0.43 RTT News13:40Biotech Pharma REGN

Market whales and their recent bets on REGN options Benzinga19:51Biotech Pharma REGN

Regeneron ’safe harbor’ argument rejected in covid cocktail suit Bloomberg Law23:05Pharma California Covid Covid Business Impact

Novartis pharma AG v. Regeneron Pharmaceuticals, Inc. (Fed. Cir. 2024) JD Supra18:52Pharma Patent Law Intellectual Property

Latest News

Yesterday

BMS, Pfizer, Regeneron, Cardinal Health and more back ‘enhanced’ thrombosis awareness campaign FiercePharma14:59 14-Oct-24

In the last 7 days

Opening doors to science with Regeneron’s Muriel O’Byrne Silicon Republic07:01 10-Oct-24

Clearside eye disease candidate aces exam in pursuit of Roche's Vabysmo and Regeneron, Bayer's… FiercePharma16:55 9-Oct-24

Regeneron Gains 13.5% Year to date: How to Play the Stock? Zacks19:35 8-Oct-24

Stock Watch: Quarter-End Jockeying At Amgen And Regeneron Scrip Pharma Intelligence14:26 8-Oct-24

In the last month

Spotlight On: Biosimilar Litigations - October 2024 JD Supra22:01 7-Oct-24

Regeneron Pharmaceuticals: Ipr&D Charge To Negatively Impact Q3 EPS By Approx. $0.43 RTT News13:40 7-Oct-24

Should You Buy the Dip on This Top Growth Stock? The Motley Fool11:32 5-Oct-24

Regeneron Can't Ax Willful Infringement In COVID Patent Case Law36001:05 5-Oct-24

Regeneron ’Safe Harbor’ Argument Rejected in Covid Cocktail Suit Bloomberg Law23:05 4-Oct-24

Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair)… GlobeNewswire (Press Release)10:47 4-Oct-24

Market Whales and Their Recent Bets on Regn Options Benzinga19:51 3-Oct-24

Amgen’s Formulation of Eylea Biosimilar Saved It From Injunction Bloomberg Law20:52 2-Oct-24

Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD PMLiVE12:56 2-Oct-24

Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last Scrip Pharma Intelligence21:42 30-Sept-24

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD Zacks19:37 30-Sept-24

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its… Simply Wall St19:36 30-Sept-24

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD Investopedia00:34 28-Sept-24

Regeneron sends up a flare in COPD with Dupixent FDA nod BioWorld21:42 27-Sept-24

FDA greenlights Regeneron’s Dupixent for the treatment of COPD Pharmaceutical Technology20:11 27-Sept-24

Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval Pharmaceutical Technology19:41 27-Sept-24

Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (Fed. Cir. 2024) JD Supra18:52 27-Sept-24

Sanofi's Dupixent scores double COPD win in US, China pharmaphorum17:11 27-Sept-24

Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback Yahoo! US16:16 27-Sept-24

AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™ PR Newswire (Press Release)15:30 27-Sept-24

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller ENDPOINTS14:48 27-Sept-24

FDA signs off on Regeneron and Sanofi's Dupixent for COPD FiercePharma14:46 27-Sept-24

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD Regeneron Pharmaceuticals (Press Release)14:40 27-Sept-24

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive… Regeneron Pharmaceuticals (Press Release)12:07 27-Sept-24

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October… Regeneron Pharmaceuticals (Press Release)21:11 26-Sept-24

Preliminary Injunction Denied Against Amgen in Aflibercept BPCIA Litigation JD Supra17:34 26-Sept-24

Preliminary Injunction Against Amgen’s EYLEA® Biosimilar Pavblu™ Denied JD Supra16:53 26-Sept-24

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors Seeking Alpha18:15 25-Sept-24

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea Zacks18:31 24-Sept-24

Regeneron hits setback in Eylea patent battle with Amgen ENDPOINTS18:23 24-Sept-24

Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar FiercePharma15:44 24-Sept-24

Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients PMLiVE12:42 24-Sept-24

Regeneron Appeals After Judge Declines to Block Amgen Biosimilar Bloomberg Law22:09 23-Sept-24

Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion Zacks19:07 23-Sept-24

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as… GlobeNewswire (Press Release)12:47 20-Sept-24

3 Genomics Stocks Transforming Healthcare Entrepreneur Magazine12:34 19-Sept-24

First Drug OK'd for Chronic Rhinosinusitis With Nasal Polyps in Adolescents Medpage Today06:33 18-Sept-24

Regeneron Slams Suit Alleging It Fired Director Over Medical Leave Law36022:54 17-Sept-24

Sanofi/Regeneron’s Dupixent granted FDA approval for adolescents with CRSwNP PMLiVE12:22 17-Sept-24

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label Zacks18:31 16-Sept-24

ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years Clinical Trials Arena11:36 16-Sept-24

Regeneron’s Dupixent approved as first adolescent CRSwNP treatment Pharmaceutical Technology10:56 16-Sept-24

'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid… FierceBiotech10:07 14-Sept-24

view more headlines

14 Oct 14:59

Regeneron News

Latest news and updates on Regeneron Pharmaceuticals, an American biotechnology company that was founded in 1988. The company is listed on NASDAQ.

Regeneron

Latest News

Regeneron News

Health Top Stories

UK Top Stories

World Top Stories